Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension

The efficacy and safety of azilsartan medoxomil (AZL‐M) were evaluated in African‐American patients with hypertension in a 6‐week, double‐blind, randomized, placebo‐controlled trial, for which the primary end point was change from baseline in 24‐hour mean systolic blood pressure (BP). There were 413...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Wallace, White, William B., Sica, Domenic, Bakris, George L., Weber, Michael A., Handley, Alison, Perez, Alfonso, Cao, Charlie, Kupfer, Stuart, Saunders, Elijah B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Hypertension Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031359/
https://www.ncbi.nlm.nih.gov/pubmed/28493376
http://dx.doi.org/10.1111/jch.12993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031359/
https://www.ncbi.nlm.nih.gov/pubmed/28493376
http://dx.doi.org/10.1111/jch.12993

Ejemplares similares